Author + information
- Received August 25, 2013
- Revision received November 25, 2013
- Accepted November 28, 2013
- Published online April 1, 2014.
- Gianluigi Savarese, MD∗,
- Francesca Musella, MD∗,
- Carmen D’Amore, MD∗,
- Enrico Vassallo, MD∗,
- Teresa Losco, MD∗,
- Francesco Gambardella, MD∗,
- Milena Cecere, MD∗,
- Laura Petraglia, MD†,
- Gennaro Pagano, MD†,
- Luigi Fimiani, MD∗,
- Giuseppe Rengo, MD†,
- Dario Leosco, MD, PhD†,
- Bruno Trimarco, MD, PhD∗ and
- Pasquale Perrone-Filardi, MD, PhD∗∗ ()
- ∗Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
- †Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy
- ↵∗Reprint requests and correspondence:
Dr. Pasquale Perrone-Filardi, Federico II University of Naples, Department of Advanced Biomedical Sciences, Division of Cardiology, Via Pansini, 5, I-80131 Naples, Italy.
Objectives The goal of this study was to explore the association between changes in B-type natriuretic peptide (BNP) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) plasma levels and risk of hospital admission for heart failure (HF) worsening in patients with chronic HF.
Background The relationship between BNP and NT-proBNP plasma levels and risk of cardiovascular events in patients with chronic HF has been previously demonstrated. However, it is unclear whether changes in BNP and NT-proBNP levels predict morbidity in patients with chronic HF.
Methods The MEDLINE, Cochrane, ISI Web of Science, and SCOPUS databases were searched for papers about HF treatment up to August 2013. Randomized trials enrolling patients with systolic HF, assessing BNP and/or NT-proBNP at baseline and at end of follow-up, and reporting hospital stay for HF were included in the analysis. Meta-regression analysis was performed to test the relationship between BNP and NT-proBNP changes and the clinical endpoint. Sensitivity analysis was performed to assess the influence of baseline variables on results. Egger's linear regression was used to assess publication bias.
Results Nineteen trials enrolling 12,891 participants were included. The median follow-up was 9.5 months (interquartile range: 6 to 18 months), and 22% of patients were women. Active treatments significantly reduced the risk of hospital stay for HF worsening. In meta-regression analysis, changes in BNP and NT-proBNP were significantly associated with risk of hospital stay for HF worsening. Results were confirmed by using sensitivity analysis. No publication bias was detected.
Conclusions In patients with HF, reduction of BNP or NT-proBNP levels was associated with reduced risk of hospital stay for HF worsening.
- B-type natriuretic peptide
- heart failure
- N-terminal pro–B-type natriuretic peptide
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 25, 2013.
- Revision received November 25, 2013.
- Accepted November 28, 2013.
- American College of Cardiology Foundation